FindTrial
Sign In

The infections caused in Acute Myeloid Leukemia patients after chemotherapy

Spectrum of Infections in Different Regimens of Post Induction Chemotherapy in Acute Myeloid Leukemia (De-Novo) - A Comparative Retrospective Study - SIAML

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/10/046636
Enrollment
420
Registered
2022-10-19
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C92A- Acute myeloid leukemia with multilineage dysplasia

Interventions

None listed

Sponsors

Jamia Hamdard
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with newly diagnosed AML

Exclusion criteria

Exclusion criteria: APML Patients whose records are incomplete or not available

Design outcomes

Primary

MeasureTime frame
To study the spectrum of infections in patients with De novo Acute Myeloid Leukemia undergoing induction chemotherapy.Timepoint: Day 7, 14, 28, First consolidation and 28 days, second consolidation and 28 days—

Secondary

MeasureTime frame
To estimate the incidence of toxicities and adverse events following the chemotherapy treatment and their managementTimepoint: Day 7, 14, and 28;To study the mortality during after induction chemotherapy.Timepoint: Day 7, 14, and 28;To study the outcome of AML patients (Remission rate and survival rate)Timepoint: Day 7, 14, and 28—

Countries

India

Contacts

Public ContactDr Dinesh Bhurani

Jamia Hamdard

makhan@jamiahamdard.ac.in9891026397

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026